Agamree (vamorolone) is the first differentiated glucocorticoid drug approved by the US FDA, designed for patients with Duchenne muscular dystrophy (DMD) aged 4 years and above. The drug balances anti-inflammatory efficacy and safety through a unique molecular structure, providing a new alternative to traditional glucocorticoids.

FDA approves Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy

Core basis for FDA approval

Based on Phase III clinical trial data, the standing time (TTSTAND) of patients in the Agamree treatment group after 48 weeks was significantly improved compared with the placebo group, and the incidence of adverse reactions such as Cushing's syndrome was reduced by about 50%. The FDA granted it priority review status and recognized its wide applicability to all DMD gene mutation types.

Differentiation advantages over traditional glucocorticoids

Agamree selectively regulates the activity of glucocorticoid receptors, retaining anti-inflammatory effects while reducing side effects such as bone metabolism inhibition and growth retardation. Studies have shown that the risk of fractures in patients with long-term use is 70% lower than that of prednisone, and the height growth rate is close to that of normal children.

The approval of Agamree provides DMD patients with a safer long-term treatment option. The following content will explain how to obtain the drug and what to pay attention to.

How to buy Agamree

The original drug Agamree is produced by Santhera Pharmaceuticals in Switzerland. Patients need to obtain it through special channels, but they need to pay attention to legal and quality risks.

Original drug prices and overseas drug purchase channels

The specification of Agamree is 40mg/mL*100mL oral suspension. Patients can purchase it through designated pharmacies or authorized medical institutions in countries where it has been listed, such as Germany and the United States. Cross-border transportation must maintain a cold chain of 2°C-8°C throughout the process to avoid drug failure.

Generic drugs and clinical trial alternatives

Currently, there are no generic drugs for Agamree on the market worldwide. Patients can pay attention to the clinical trial project of new DMD drugs. Eligible patients have the opportunity to receive free treatment, and rare disease charity organizations can help connect with international medical resources.

After obtaining the drug, the correct storage method is crucial. The following content will detail the storage requirements of Agamree.

Storage conditions of Agamree

Agamree is an oral suspension preparation, and its stability is significantly affected by temperature and light. Strictly following storage specifications can maximize the maintenance of drug activity.

Storage specifications for unopened drugs

Unopened Agamree should be stored upright at room temperature of 20°C-25°C, and short exposure to 15°C-30°C is allowed. It should be kept away from direct sunlight, and the original aluminum foil bag can effectively isolate moisture. A special cold chain box should be used during transportation, and it is prohibited to use it when the temperature fluctuates more than 30°C.

Use and disposal after opening

It must be refrigerated (2°C-8°C) after opening, and shake well for 30 seconds before each use. The suspension that is not used up within 3 months after opening the bottle should be discarded, and freezing or repeated heating is prohibited. The dedicated oral syringe equipped needs to be cleaned with sterile water every month to avoid cross contamination.

Check the properties of the drug regularly, and stop using it immediately if stratification, discoloration or odor occurs. During treatment, bone density and adrenal function need to be monitored monthly, and a high-calcium diet and vitamin D supplementation are required. If mood swings or blurred vision occur, the attending physician should be contacted in time to adjust the treatment plan. Through standardized medication and scientific management, Agamree is expected to provide DMD patients with more lasting motor function protection and improved quality of life.